CA-PONY.AI
7.3.2024 08:55:29 CET | Business Wire | Press release
Pony.ai, a leading global autonomous mobility company, held a Memorandum of Understanding (MoU) signing ceremony today with the Government of the Grand Duchy of Luxembourg (“The Government”) to advance the development of autonomous mobility in Luxembourg. The MoU was signed by Pony.ai Co-Founder and CEO Dr. James Peng and Luxembourg’s Minister of the Economy Lex Delles. This MoU represents a collaborative partnership between Luxembourg and Pony.ai, with the objective of fostering the research, development, and deployment of autonomous vehicles in Luxembourg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306928526/en/
Delegation from the Government of the Grand Duchy of Luxembourg visits Pony.ai’s office in Fremont, California, March 6, 2024 (Photo: Business Wire)
As a global leader in innovation and technology, Luxembourg presents an excellent opportunity for Pony.ai to further develop its leading autonomous mobility technology in Europe. Pony.ai, with the support of Luxinnovation and local stakeholders, intends to set up a regional hub in Luxembourg, which will serve as a center for Pony.ai’s cutting-edge research and development of autonomous vehicle technology. Pony.ai’s Luxembourg-based hub will be pivotal in driving technological advancements and tailoring solutions for the European market. In addition, the Government and Pony.ai aim to develop a robust local network to support operational capabilities in Luxembourg. Pony.ai looks forward to building strong local partnerships to support this effort.
Pony.ai co-founder and CEO Dr. James Peng said: “As a leading global autonomous vehicle company, Pony.ai is delighted to partner with Luxembourg as we continue our global expansion. We aim to bring to this partnership our cutting-edge AV technology, comprehensive training programs, and a commitment to establish a regional hub in Luxembourg as we continue our global expansion.”
Luxembourg Minister of the Economy Lex Delles said: “The intelligent mobility sector is one of our priorities with regard to the diversification of Luxembourg’s economy. Our aim is to make the Grand Duchy a pioneer in the field of autonomous driving on a European scale. As such, I am very pleased with the signature of an MoU with Pony.ai, a leader in autonomous mobility technologies and services. The signature today formalizes our collaboration and is an important step towards creating a synergy between the technical expertise of Pony.ai and the Luxembourg government's political strategy. The latter aims to promote research and technological development, job creation and sustainable economic growth.”
Pony.ai is a leader in autonomous mobility and in the commercialization of autonomous driving, operating Robotaxi, Robotruck and Personally Owned Vehicle (POV) business units, developing the safest autonomous driving capabilities on a global scale. Pony.ai is excited to continue its expansion into Luxembourg and the European market. For the past year, Pony.ai has engaged in detailed conversations surrounding robotaxi deployment use cases and opportunities with local stakeholders in Luxembourg and believes the country is an exciting and innovative region to introduce Pony.ai’s leading autonomous vehicles.
About Pony.ai
Leading global autonomous driving company Pony.ai, Inc. (“Pony.ai”) is pursuing an ambitious vision for autonomous mobility. We aim to bring safe, sustainable, and accessible mobility to the entire world. We believe that autonomous technology can make our roads exponentially safer for travelers. Founded in late 2016, Pony.ai has been a pioneer in extending autonomous mobility technologies and services at a rapidly expanding footprint of sites around the world. Pony.ai has formed partnerships with leading OEMs, including Toyota, SAIC, SANY, FAW Group, GAC Group, etc. To date, Pony.ai has driven over 30 million autonomous testing and operation kilometers (over 18.6 million miles) on open roads worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306928526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom